CA2198899A1 - Methods for producing antibody libraries using universal or randomized immunoglobulin light chains - Google Patents

Methods for producing antibody libraries using universal or randomized immunoglobulin light chains

Info

Publication number
CA2198899A1
CA2198899A1 CA002198899A CA2198899A CA2198899A1 CA 2198899 A1 CA2198899 A1 CA 2198899A1 CA 002198899 A CA002198899 A CA 002198899A CA 2198899 A CA2198899 A CA 2198899A CA 2198899 A1 CA2198899 A1 CA 2198899A1
Authority
CA
Canada
Prior art keywords
oligonucleotide
immunoglobulin
light chain
gene
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002198899A
Other languages
French (fr)
Other versions
CA2198899C (en
Inventor
Carlos F. Barbas
Dennis R. Burton
Richard A. Lerner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Carlos F. Barbas
Dennis R. Burton
Richard A. Lerner
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carlos F. Barbas, Dennis R. Burton, Richard A. Lerner, The Scripps Research Institute filed Critical Carlos F. Barbas
Publication of CA2198899A1 publication Critical patent/CA2198899A1/en
Application granted granted Critical
Publication of CA2198899C publication Critical patent/CA2198899C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Abstract

The present invention describes methods for producing antibody libraries, and particularly for increasing antibody library diversity by inducing mutagenesis within the CDR regions of immunoglobulun heavy or light chains that are displayed on the surface of filamentous phage particles comprising the library. The invention also describes oligonucleotides useful for increasing the library diiversity, and universal light chains useful in the library production methods.

Claims (37)

1. An oligonucleotide useful as a primer for inducing mutagenesis in a complementarity determining region (CDR) of an immunoglobulin light chain gene, said oligonucleotide having 3' and 5' termini and comprising:
a) a nucleotide sequence at said 3' terminus capable of hybridizing to a first framework region of an immunoglobulin gene;
b) a nucleotide sequence at said 5' terminus capable of hybridizing to a second framework region of an immunoglobulin gene; and c) a nucleotide sequence between said 3' and 5' termini according to the formula:
[NNK]n, wherein N is independently any nucleotide, K is G or T, n is 3 to about 24, said 3' and 5' terminal nucleotide sequences having a length of about 6 to 50 nucleotides, or an oligonucleotide having a sequence complementary thereto.
2. The oligonucleotide of claim 1 wherein said 5' terminus has the nucleotide sequence 5' -TATACTGTCAGCAGTAT-3' (SEQ ID NO
26) or 5' -GATTTTGCAGTGTATTACTGTCAGQGTAT-3' (SEQ ID NO 27), or an oligonucleotide having a sequence complementary thereto.
3. The oligonucleotide of claim 1 wherein said 3' terminus has the nucleotide sequence 5' -ACTTTCGGCGGAGGGACQAGGTGGAG-3' (SEQ ID NO 28) or 5' -ACTTTCGGCGGAGGGACC-3' (SEQ ID NO 29), or an oligonucleotide having a sequence complementary thereto.
4. The oligonucleotide of claim 1 wherein n is 4, 5, 6, 10 or 16.
5. The oligonucleotide of claim 1 wherein said immunoglobulin is human.
6. The oligonucleotide of claim 1 wherein said CDR is CDR3.
7. The oligonucleotide of claim 1 according to the formula: 5' -GATTTTGCAGTGTATTACTGT [NNK] 10TTCGGCGGAGGGACCAAGGTGGAG-3' (SEQ ID NO 12), or an oligonucleotide having a sequence complementary thereto.
8. An oligonucleotide useful as a primer for inducing mutagenesis in a complementarity determining region (CDR) of an immunoglobulin light chain gene, said oligonucleotide having 3' and 5' termini and comprising:
a) a nucleotide sequence at said 3' terminus capable of hybridizing to a first framework region of an immunoglobulin gene;
b) a nucleotide sequence at said 5' terminus capable of hybridizing to a second framework region of an immunoglobulin gene; and c) a nucleotide sequence between said 3' and 5' termini according to the formula:
[MNN]n, wherein N is independently any nucleotide, M is A or C, n is 3 to about 24, said 3' and 5' terminal nucleotide sequences having a length of about 6 to 50 nucleotides, or an oligonucleotide having a sequence complementary thereto.
9 . The oligonucleotide of claim 8 wherein said 5' terminus has the nucleotide sequence 5' -GTTCCACCTTGGTCCCTTGGCCGAA-3' (SEQ
ID NO 30), or an oligonucleotide having a sequence complementary thereto.
10. The oligonucleotide of claim 8 wherein said 3' terminus has the nucleotide sequence 5' -ACAGTAGTACACTGCAAAATC-3' (SEQ ID
NO 31), or an oligonucleotide having a sequence complementary thereto.
11. The oligonucleotide of claim 8 wherein n is 8, 10 or 16.
12. The oligonucleotide of claim 8 wherein said immunoglobulin is human.
13. The oligonucleotide of claim 8 wherein said CDR is CDR3.
14. A method for producing an antibody combining site in a polypeptide comprising inducing mutagenesis in a complementarity determining region (CDR) of an immunoglobulin light chain gene which comprises amplifying a CDR portion of the immunoglobulin gene by polymerase chain reaction (PCR) using a PCR primer oligonucleotide, said oligonucleotide having 3' and 5' termini and comprising:
a) a nucleotide sequence at said 3' terminus capable of hybridizing to a first framework region of an immunoglobulin gene;
b) a nucleotide sequence at said 5' terminus capable of hybridizing to a second framework region of an immunoglobulin gene; and c) a nucleotide sequence between said 3' and 5' termini according to the formula:
[NNK]n, wherein N is independently any nucleotide, K is G or T, and n is 3 to about 24, said 3' and 5' terminal nucleotide sequences having a length of about 6 to 50 nucleotides, or an oligonucleotide having a sequence complementary thereto.
15. The method of claim 14 wherein said 5' terminus has the nucleotide sequence 5'-TATACTGTCAGCAGTAT-3' (SEQ ID NO 26) or 5'-GATTTTGCAGTGTATTACTGTCAGCAGTAT-3' (SEQ ID NO 27), or an oligonucleotide having a sequence complementary thereto.
16 . The method of claim 14 wherein said 3' terminus has the nucleotide sequence 5' -ACTTTCGGCGGAGGGACCAAGGTGGAG-3' (SEQ ID NO
28) or 5' -ACTTTCGGCGGAGGGACC-3' (SEQ ID NO 29), or an oligonucleotide having a sequence complementary thereto.
17. The method of claim 14 wherein n is 4, 5, 6, 10 or 16.
18. The method of claim 14 wherein said immunoglobulin is human.
19. The method of claim 14 wherein said CDR is CDR3.
20. The method of claim 14 according to the formula:
5'-GATTTTGCAGTGTATTACTGT [NNK]10TTCGGCGGAGGGCCAAGGTGGAG-3' (SEQ ID NO
12), or an oligonucleotide having a sequence complementary thereto.
21. The method of claim 14 wherein said immunoglobulin light chain gene includes a sequence having the sequence characteristics of the light chain shown in SEQ ID NO 2 or in SEQ
ID NO 62.
22. The method of claim 14 wherein said immunoglobulin light chain gene has the sequence characteristics of the light chain gene in ATCC Accession No. 75408.
23. The method of claim 14 that further comprises the steps of:
a) isolating the amplified CDR to form a library of mutagenized immunoglobulin light chain genes;
b) expressing the isolated library of mutagenized light chain genes in combination with one or more heavy chain genes to form a combinatorial antibody library of expressed heavy and light chain genes; and c) selecting species of said combinatorial antibody library for the ability to bind a preselected antigen.
24. The method of claim 23 wherein said one or more immunoglobulin heavy chain genes is a library of heavy chain genes.
25. A method for producing an antibody combining site in a polypeptide comprising inducing mutagenesis in a complementarity determining region (CDR) of an immunoglobulin light chain gene which comprises amplifying a CDR portion of the immunoglobulin gene by polymerase chain reaction (PCR) using a PCR primer oligonucleotide, said oligonucleotide having 3' and 5' termini and comprising:
a) a nucleotide sequence at said 3' terminus capable of hybridizing to a first framework region of an immunoglobulin gene;
b) a nucleotide sequence at said 5' terminus capable of hybridizing to a second framework region of an immunoglobulin gene; and c) a nucleotide sequence between said 3' and 5' termini according to the formula:
[MNN]n, wherein N is independently any nucleotide, M is A or C, n is 3 to about 24, said 3' and 5' terminal nucleotide sequences having a length of about 6 to 50 nucleotides, or an oligonucleotide having a sequence complementary thereto.
26. The method of claim 25 wherein said 5' terminus has the nucleotide sequence 5'-GTTCCACCTTGGTCCCTTGGCCGAA-3' (SEQ ID NO
30), or an oligonucleotide having a sequence complementary thereto.
27. The method of claim 25 wherein said 3' terminus has the nucleotide sequence 5'-ACAGTAGTACACTGCAAAATC-3' (SEQ ID NO 31), or an oligonucleotide having a sequence complementary thereto.
28. The method of claim 25 wherein n is 8, 10 or 16.
29. The method of claim 25 wherein said immunoglobulin is human.
30. The method of claim 25 wherein said CDR is CDR3.
31. The method of claim 25 wherein said immunoglobulin light chain gene includes a sequence having the sequence characteristics of the light chain shown in SEQ ID NO 2 or in SEQ
ID NO 62.
32. The method of claim 25 wherein said immunoglobulin light chain gene has the sequence characteristics of the light chain gene in ATCC Accession No. 75408.
33. The method of claim 25 that further comprises the steps of:
a) isolating the amplified CDR to form a library of mutagenized immunoglobulin light chain genes;
b) expressing the isolated library of mutagenized light chain genes in combination with one or more heavy chain genes to form a combinatorial antibody library of expressed heavy and light chain genes; and c) selecting species of said combinatorial antibody library for the ability to bind a preselected antigen.
34. The method of claim 33 wherein said one or more immunoglobulin heavy chain genes is a library of heavy chain genes.
35. A method for producing a heterodimeric immunoglobulin molecule having immunoglobulin variable domain heavy and light chain polypeptides comprising the steps of:
a) combining an immunoglobulin variable domain light chain gene that includes a sequence having the sequence characteristics of the light chain shown in SEQ ID NO 2 or 62 with one or more immunoglobulin variable domain heavy chain genes to form a combinatorial immunoglobulin heavy and light chain gene library, said combining comprising operatively linking said light chain gene with one of said heavy chain genes in a vector capable of co-expression of said heavy and light chain genes;
b) expressing the combinatorial gene library to form a combinatorial antibody library of expressed heavy and light chain polypeptides; and c) selecting species of said combinatorial antibody library for the ability to bind a preselected antigen.
36. The method of claim 35 wherein said immunoglobulin light chain gene has the sequence characteristics of the light chain gene in ATCC Accession No. 75408.
37. The method of claim 35 wherein said one or more immunoglobulin heavy chain genes is a library of heavy chain genes.
CA2198899A 1994-09-02 1995-09-01 Methods for producing antibody libraries using universal or randomized immunoglobulin light chains Expired - Lifetime CA2198899C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/300,386 US5667988A (en) 1992-01-27 1994-09-02 Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US08/300,386 1994-09-02
PCT/US1995/011235 WO1996007754A1 (en) 1994-09-02 1995-09-01 Methods for producing antibody libraries using universal or randomized immunoglobulin light chains

Publications (2)

Publication Number Publication Date
CA2198899A1 true CA2198899A1 (en) 1996-03-14
CA2198899C CA2198899C (en) 2010-02-23

Family

ID=23158889

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2198899A Expired - Lifetime CA2198899C (en) 1994-09-02 1995-09-01 Methods for producing antibody libraries using universal or randomized immunoglobulin light chains

Country Status (11)

Country Link
US (2) US5667988A (en)
EP (1) EP0779933B1 (en)
JP (1) JPH10504970A (en)
AT (1) ATE236992T1 (en)
AU (1) AU706343B2 (en)
CA (1) CA2198899C (en)
DE (1) DE69530305T2 (en)
DK (1) DK0779933T3 (en)
ES (1) ES2196077T3 (en)
PT (1) PT779933E (en)
WO (1) WO1996007754A1 (en)

Families Citing this family (356)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6235294A (en) * 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing polypeptide binding sites
US20060078561A1 (en) * 1994-01-31 2006-04-13 The Trustees Of Boston University Polyclonal antibody libraries
DK0744958T3 (en) 1994-01-31 2003-10-20 Univ Boston Polyclonal antibody libraries
DK1143006T3 (en) * 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vectors / DNA sequences from human combinatorial antibody libraries
US6017754A (en) * 1995-08-24 2000-01-25 Invitrogen Corporation System for isolating and identifying eukaryotic cells transfected with genes and vectors, host cells and methods thereof
FR2741892B1 (en) 1995-12-04 1998-02-13 Pasteur Merieux Serums Vacc METHOD FOR PREPARING A MULTI-COMBINED BANK OF ANTIBODY GENE EXPRESSION VECTORS, BANK AND COLICLONAL ANTIBODY EXPRESSION SYSTEMS
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US6590079B2 (en) * 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US6596850B1 (en) * 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
US6057098A (en) * 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
EP0985033A4 (en) * 1997-04-04 2005-07-13 Biosite Inc Polyvalent and polyclonal libraries
GB9722131D0 (en) * 1997-10-20 1997-12-17 Medical Res Council Method
US6759243B2 (en) * 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
EP2311490A3 (en) 1998-07-13 2011-05-04 Board of Regents, The University of Texas System Uses of antibodies to aminophospholipids for cancer treatment
IL140918A0 (en) 1998-07-27 2002-02-10 Genentech Inc Improved transformation efficiency in phage display through modification of a coat protein
US6531580B1 (en) * 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
US20070111259A1 (en) * 1999-10-02 2007-05-17 Medarex, Inc. Human antibodies
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
US7135287B1 (en) 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US6680209B1 (en) * 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
JP2003516755A (en) * 1999-12-15 2003-05-20 ジェネンテック・インコーポレーテッド Shotgun scanning, a combined method for mapping functional protein epitopes
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
AU2001240020B9 (en) * 2000-03-01 2008-12-04 Medimmune, Llc High potency recombinant antibodies and method for producing them
DK1265928T3 (en) * 2000-01-27 2010-11-15 Medimmune Llc RSV neutralizing antibodies with ultra high affinity
UA81743C2 (en) 2000-08-07 2008-02-11 Центокор, Инк. HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
CA2450236A1 (en) * 2001-07-06 2003-01-16 Genentech, Inc. Phage displayed pdz domain ligands
US20030104604A1 (en) * 2001-08-03 2003-06-05 Weiping Yang Genetically engineered bacterial strains for the display of foreign peptides on filamentous phage
DE60232688D1 (en) 2001-11-20 2009-07-30 Univ Duke BOUNDARY-BIOMATERIALS
GB0202206D0 (en) * 2002-01-31 2002-03-20 Bioinvent Int Ab Method of making libraries of anti-ligands
US7504364B2 (en) * 2002-03-01 2009-03-17 Receptors Llc Methods of making arrays and artificial receptors
US7244592B2 (en) 2002-03-07 2007-07-17 Dyax Corp. Ligand screening and discovery
DE60328674D1 (en) * 2002-04-17 2009-09-17 Bioren Inc UNIVERSAL BANKS FOR IMMUNOGLOBULINE
US7405062B2 (en) * 2002-05-14 2008-07-29 San Diego Antibody Method for cloning variable domain sequences of immunological gene repertoire
EP1513879B1 (en) * 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040175378A1 (en) 2002-07-15 2004-09-09 Board Of Regents, The University Of Texas System Selected antibody compositions and methods for binding to aminophospholipids
PT2314629E (en) * 2002-07-18 2014-01-22 Merus B V Recombinant production of mixtures of antibodies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
TW200501985A (en) * 2002-07-25 2005-01-16 Medimmune Inc Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US7469076B2 (en) * 2003-09-03 2008-12-23 Receptors Llc Sensors employing combinatorial artificial receptors
WO2005003326A2 (en) * 2003-03-28 2005-01-13 Receptors Llc. Artificial receptors including reversibly immobilized building blocks and methods
US20060057625A1 (en) * 2002-09-16 2006-03-16 Carlson Robert E Scaffold-based artificial receptors and methods
US20050037428A1 (en) * 2002-09-16 2005-02-17 Receptors Llc Artificial receptors including reversibly immobilized building blocks, the building blocks, and methods
US20040137481A1 (en) * 2002-09-16 2004-07-15 Receptors Llc Artificial receptor building blocks, components, and kits
US20050037429A1 (en) * 2003-03-28 2005-02-17 Receptors Llc Artificial receptors including reversibly immobilized building blocks and methods
US20050170385A1 (en) * 2002-09-16 2005-08-04 Receptors Llc Artificial receptors including gradients
US20050037381A1 (en) * 2002-09-16 2005-02-17 Receptors Llc Artificial receptors, building blocks, and methods
US20050136483A1 (en) * 2003-09-03 2005-06-23 Receptors Llc Nanodevices employing combinatorial artificial receptors
HUE034378T2 (en) 2002-10-16 2018-02-28 Purdue Pharma Lp Antibodies that bind cell-associated CA 125/O722P and methods of use thereof
US7427469B2 (en) * 2002-11-05 2008-09-23 Institut Pasteur Method of treating cytomegalovirus with DC-SIGN blockers
AU2003301804A1 (en) * 2002-11-05 2004-06-07 Institut National De La Sante Et De La Recherche Medicale Dc-sign blockers and their use for preventing or treating viral infections.
WO2004044161A2 (en) * 2002-11-06 2004-05-27 Fraunhofer Usa Expression of foreign sequences in plants using trans-activation system
US7692063B2 (en) * 2002-11-12 2010-04-06 Ibio, Inc. Production of foreign nucleic acids and polypeptides in sprout systems
US7683238B2 (en) * 2002-11-12 2010-03-23 iBio, Inc. and Fraunhofer USA, Inc. Production of pharmaceutically active proteins in sprouted seedlings
US20050079574A1 (en) * 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
AU2004209660A1 (en) 2003-02-03 2004-08-19 Fraunhofer Usa, Inc. System for expression of genes in plants
WO2004072266A2 (en) * 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
DE602004025332D1 (en) 2003-03-14 2010-03-18 Wyeth Corp ANTIBODY TO IL21 RECEPTOR AND ITS USE
AU2004272972A1 (en) 2003-05-22 2005-03-24 Fraunhofer Usa, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
ES2408582T3 (en) 2003-05-30 2013-06-21 Merus B.V. Fab library for the preparation of a mixture of antibodies
EP2508608A1 (en) 2003-06-09 2012-10-10 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
WO2005011580A2 (en) * 2003-07-25 2005-02-10 Board Of Regents, The University Of Texas System Compositions and methods for herpes simplex prophylaxis and treatment
CA2534055A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
WO2005035569A2 (en) * 2003-10-10 2005-04-21 Five Prime Therapeutics, Inc. Kiaa0779, splice variants thereof, and methods of their use
US7329725B1 (en) * 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
EP1697534B1 (en) 2003-12-01 2010-06-02 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
EP1761561B1 (en) 2004-01-20 2015-08-26 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
WO2005081905A2 (en) * 2004-02-20 2005-09-09 Fraunhofer Usa Inc. Systems and methods for clonal expression in plants
US7785903B2 (en) * 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
US20060292554A1 (en) * 2004-05-18 2006-12-28 Genentech, Inc. Major coat protein variants for C-terminal and bi-terminal display
ATE462451T1 (en) 2004-06-16 2010-04-15 Affinergy Inc INTERFACE BIOMATERIALS TO PROMOTE ADHESION OF TARGET ANALYTES
EP1781680B8 (en) * 2004-07-06 2016-05-18 Bioren, LLC Universal antibody libraries
EP1791975A4 (en) * 2004-08-05 2007-11-07 Biosite Inc Compositions and methods for phage display of polypeptides
US7504365B2 (en) 2004-09-03 2009-03-17 Receptors Llc Combinatorial artificial receptors including tether building blocks
WO2006029383A2 (en) * 2004-09-11 2006-03-16 Receptors Llc Combinatorial artificial receptors including peptide building blocks
EP1812068A4 (en) * 2004-10-29 2010-06-09 Medimmune Inc Methods of preventing and treating rsv infections and related conditions
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
WO2006109592A1 (en) * 2005-04-08 2006-10-19 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
HUE030701T2 (en) 2005-05-27 2017-05-29 Biogen Ma Inc Tweak binding antibodies
EP1919504B1 (en) * 2005-08-03 2013-10-16 iBio, Inc. Antibody to bacillus anthracis protective antigen
IL172297A (en) 2005-10-03 2016-03-31 Compugen Ltd Soluble vegfr-1 variants for diagnosis of preeclamsia
WO2007048127A2 (en) * 2005-10-20 2007-04-26 The Scripps Research Institute Fc labeling for immunostaining and immunotargeting
ES2577292T3 (en) 2005-11-07 2016-07-14 Genentech, Inc. Binding polypeptides with diversified VH / VL hypervariable sequences and consensus
US8716195B2 (en) * 2005-11-14 2014-05-06 Bioren, Inc. Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening
CA2626522A1 (en) 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
US20070237764A1 (en) * 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
EP2325208B1 (en) 2005-12-15 2017-09-20 Genentech, Inc. Polyubiquitin antibodies
AU2007248444B2 (en) 2006-01-05 2012-10-25 Genentech, Inc. Anti-EphB4 antibodies and methods using same
US20100184021A1 (en) 2006-01-16 2010-07-22 Compugen Ltd. Novel nucleotide and amino acid sequences, and methods of use thereof for diagnosis
WO2007092777A2 (en) * 2006-02-02 2007-08-16 Wyeth Cloning, characterization, and application of tnfrsf19 in neurological disorders
WO2008048344A2 (en) * 2006-02-13 2008-04-24 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
EP1984405A4 (en) * 2006-02-13 2010-06-30 Fraunhofer Usa Inc Influenza antigens, vaccine compositions, and related methods
CA2642056A1 (en) * 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Hpv antigens, vaccine compositions, and related methods
AR059851A1 (en) 2006-03-16 2008-04-30 Genentech Inc ANTIBODIES OF EGFL7 AND METHODS OF USE
US7833724B2 (en) * 2006-03-20 2010-11-16 Teva Women's Health, Inc. Methods for comparing the immunogenicity of products and uses thereof
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP3345616A1 (en) 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
WO2007134050A2 (en) * 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
US8148085B2 (en) 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
EP2522678A1 (en) * 2006-05-15 2012-11-14 Sea Lane Biotechnologies, LLC Neutralizing antibodies to influenza viruses
RU2436796C9 (en) 2006-05-30 2013-12-27 Дженентек, Инк. Antibodies and immunoconjugates and their application
EP2032604A2 (en) 2006-06-06 2009-03-11 Genentech, Inc. Anti-dll4 antibodies and methods using same
CA2657576C (en) 2006-07-14 2023-10-31 The Regents Of The University Of California Cancer biomarkers and methods of use thereof
US20090252745A1 (en) * 2006-09-15 2009-10-08 Duke University Amino acids in the HCV core polypeptide domain 3 and correlation with steatosis
DK2069558T3 (en) 2006-10-02 2013-08-05 Sea Lane Biotechnologies Llc Design and construction of diverse synthetic peptide and polypeptide libraries
KR101541550B1 (en) 2006-10-27 2015-08-04 제넨테크, 인크. Antibodies and immunoconjugates and uses therefor
AU2008205330B2 (en) 2007-01-08 2014-07-03 Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services SLCO1B3 genotype
US9068003B2 (en) 2007-01-10 2015-06-30 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
US9896511B2 (en) 2007-01-10 2018-02-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
US8778348B2 (en) * 2007-04-28 2014-07-15 Ibio Inc. Trypanosoma antigens, vaccine compositions, and related methods
EP1997830A1 (en) * 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
EP2178558B1 (en) 2007-07-11 2014-04-30 iBio, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
SG183044A1 (en) 2007-07-16 2012-08-30 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugatesand methods of use
ES2381788T3 (en) 2007-07-16 2012-05-31 Genentech, Inc. Anti-CD79b and immunoconjugate antibodies and methods of use
US20110059130A1 (en) * 2007-08-20 2011-03-10 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions and methods
WO2009026496A1 (en) * 2007-08-22 2009-02-26 University Of Southern California Grp78 and tumor angiogenesis
WO2009036379A2 (en) * 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
WO2009054435A1 (en) 2007-10-24 2009-04-30 Otsuka Chemical Co., Ltd. Polypeptide having enhanced effector function
JP5809415B2 (en) 2007-11-09 2015-11-10 ペレグリン ファーマシューティカルズ，インコーポレーテッド Compositions and methods of anti-VEGF antibodies
TWI580694B (en) 2007-11-30 2017-05-01 建南德克公司 Anti-vegf antibodies
US8133488B2 (en) 2008-01-18 2012-03-13 Genentech, Inc. Methods and compositions for targeting polyubiquitin
UA106586C2 (en) 2008-01-31 2014-09-25 Дженентек, Інк. Anti-cd79b antibodies and imunokonugate and methods for their use
LT2708559T (en) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CA2724415C (en) * 2008-05-15 2016-09-13 Selexys Pharmaceuticals Corporation Anti-psgl-1 antibodies and methods of identification and use
US20090291073A1 (en) * 2008-05-20 2009-11-26 Ward Keith W Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
JP2009278908A (en) * 2008-05-22 2009-12-03 Fujifilm Corp Anti-osteocalcin antibody and immunity-measuring method using the same
EP2303318A2 (en) 2008-06-20 2011-04-06 Wyeth LLC Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains
US8680020B2 (en) 2008-07-15 2014-03-25 Academia Sinica Glycan arrays on PTFE-like aluminum coated glass slides and related methods
CN102159243B (en) * 2008-07-21 2015-08-19 免疫医疗公司 For the structural variant of the antibody for the treatment of feature improved
WO2010017598A1 (en) 2008-08-14 2010-02-18 Arana Therapeutics Limited Anti-il-12/il-23 antibodies
WO2010019120A1 (en) 2008-08-15 2010-02-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health S0x9, prostaglandin d2 and retinoic acid for treating pigmentary conditions and melanoma
WO2010033229A2 (en) 2008-09-22 2010-03-25 Calmune Corporation Methods and vectors for display of molecules and displayed molecules and collections
WO2010033237A2 (en) * 2008-09-22 2010-03-25 Calmune Corporation Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
EP3025727A1 (en) 2008-10-02 2016-06-01 The J. David Gladstone Institutes Methods of treating liver disease
EP2361093A2 (en) 2008-11-26 2011-08-31 Five Prime Therapeutics, Inc. Compositions and methods for regulating collagen and smooth muscle actin expression by serpine2
WO2010061393A1 (en) 2008-11-30 2010-06-03 Compugen Ltd. He4 variant nucleotide and amino acid sequences, and methods of use thereof
CN101768213B (en) 2008-12-30 2012-05-30 中国科学院遗传与发育生物学研究所 Protein related to plant tillering number and coding gene and application thereof
CN101817879A (en) 2009-02-26 2010-09-01 中国科学院遗传与发育生物学研究所 Metallothionein and encoding gene and application thereof
EP2679600A1 (en) 2009-03-25 2014-01-01 Genentech, Inc. Anti-FGFR3 antibodies and methods using same
RU2587621C2 (en) 2009-04-01 2016-06-20 Дженентек, Инк. ANTI-FcRH5 ANTIBODIES, IMMUNOCONJUGATES THEREOF AND METHODS FOR USE THEREOF
WO2010129033A2 (en) * 2009-04-29 2010-11-11 Calmune Corporation Modified antibodies for passive immunotherapy
JP5797642B2 (en) * 2009-05-20 2015-10-21 ノビミューン エスアー Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
DK2435568T3 (en) 2009-05-29 2014-09-08 Morphosys Ag Collection of synthetic antibodies to treat disease
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
ES2553440T3 (en) * 2009-08-13 2015-12-09 Crucell Holland B.V. Antibodies against human respiratory syncytial virus (RSV) and method of use
AU2010289400B2 (en) 2009-09-02 2014-10-23 Curis, Inc. Mutant smoothened and methods of using the same
US20110189183A1 (en) 2009-09-18 2011-08-04 Robert Anthony Williamson Antibodies against candida, collections thereof and methods of use
WO2011041391A1 (en) 2009-09-29 2011-04-07 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
CA2778481A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Anti-hepsin antibodies and methods using same
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
EP2496600A1 (en) 2009-11-04 2012-09-12 Fabrus LLC Methods for affinity maturation-based antibody optimization
EP2496601B1 (en) 2009-11-05 2017-06-07 F. Hoffmann-La Roche AG Methods and composition for secretion of heterologous polypeptides
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
TWI505836B (en) 2009-12-11 2015-11-01 Genentech Inc Anti-vegf-c antibodies and methods using same
SG2014011340A (en) 2009-12-21 2014-07-30 Genentech Inc Antibody formulation
MX2012007379A (en) 2009-12-23 2012-08-31 Genentech Inc Anti-bv8 antibodies and uses thereof.
US8685524B2 (en) 2010-01-29 2014-04-01 Toray Industries, Inc. Polylactic acid-based resin sheet
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
AU2011213585B2 (en) * 2010-02-08 2014-02-06 Regeneron Pharmaceuticals, Inc. Common light chain mouse
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
EP3508854A1 (en) 2010-04-27 2019-07-10 The Regents of The University of California Cancer biomarkers and methods of use thereof
JP5947289B2 (en) 2010-05-10 2016-07-06 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Determination of the susceptibility of zanamivir phosphonate congeners with anti-influenza activity and influenza virus to oseltamivir
KR20130098165A (en) 2010-06-03 2013-09-04 제넨테크, 인크. Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
AR082149A1 (en) 2010-07-09 2012-11-14 Calmune Corp ANTIBODIES AGAINST HUMAN RESPIRATORY SYNTHETIC VIRUS (RSV) AND METHODS FOR USE
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
MX2013002255A (en) 2010-08-27 2013-07-03 Stem Centrx Inc Notum protein modulators and methods of use.
CA2810016A1 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
MX349622B (en) 2010-09-08 2017-08-07 Halozyme Inc Methods for assessing and identifying or evolving conditionally active therapeutic proteins.
WO2012047968A2 (en) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened and methods of using the same
EP2632489B1 (en) 2010-10-27 2020-01-15 The Research Foundation for The State University of New York Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
HUE038305T2 (en) 2010-11-17 2018-10-29 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
ES2696548T3 (en) 2010-11-19 2019-01-16 Morphosys Ag A collection of antibody sequences and their use
CA2820885A1 (en) 2010-12-08 2012-09-07 Stem Centrx, Inc. Novel modulators and methods of use
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
SA112330278B1 (en) 2011-02-18 2015-10-09 ستيم سينتركس، انك. Novel modulators and methods of use
CN103619877B (en) 2011-04-21 2018-01-02 加文医学研究所 The variable domains molecule and its generation and application method B of modification
WO2013022782A1 (en) 2011-08-05 2013-02-14 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
CN104053779B (en) 2011-09-28 2017-05-24 时代生物技术股份公司 Split inteins and uses thereof
JP5936145B2 (en) * 2011-09-29 2016-06-15 Ｎｅｃソリューションイノベータ株式会社 Nucleic acid construct used for screening of peptide antibody and screening method using the same
EP2762493B1 (en) 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
WO2013065708A1 (en) 2011-10-31 2013-05-10 中外製薬株式会社 Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
AU2013208007A1 (en) 2012-01-09 2014-07-31 The Scripps Research Institute Humanized antibodies with ultralong CDR3
JP6684490B2 (en) 2012-01-09 2020-04-22 ザ・スクリップス・リサーチ・インスティテュート Ultralong complementarity determining regions and uses thereof
CA2865404C (en) 2012-02-24 2019-08-27 Stem Centrx, Inc. Dll3-binding antibodies and drug conjugates thereof to treat cancer
US20140170159A9 (en) 2012-03-08 2014-06-19 Ge Wei Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
AU2013204581B2 (en) 2012-03-16 2015-06-25 Regeneron Pharmaceuticals, Inc. Non-human animals expressing pH-sensitive immunoglobulin sequences
CA2865643A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
RU2664473C2 (en) 2012-03-16 2018-08-17 Регенерон Фармасьютикалз, Инк. Non-human animals expressing ph-sensitive immunoglobulin sequences
US20140087362A1 (en) 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
HUE045944T2 (en) 2012-04-20 2020-02-28 Merus Nv Methods and means for the production of heterodimeric ig-like molecules
DK2692865T3 (en) * 2012-07-30 2015-02-16 Nbe Therapeutics Llc Transponeringsmedieret identification of specific binding proteins, or functional
JP6302909B2 (en) 2012-08-18 2018-03-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Cell-permeable probes for sialidase identification and imaging
AU2013305827A1 (en) 2012-08-21 2015-03-05 Academia Sinica Benzocyclooctyne compounds and uses thereof
PT2928923T (en) 2012-12-10 2020-03-27 Biogen Ma Inc Anti-blood dendritic cell antigen 2 antibodies and uses thereof
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
PL2958944T3 (en) 2013-02-22 2019-09-30 Abbvie Stemcentrx Llc Antidll3-antibody-pbd conjugates and uses thereof
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
MY189047A (en) 2013-03-13 2022-01-21 Genentech Inc Antibody formulations
BR112015022484A2 (en) 2013-03-13 2017-07-18 Genentech Inc reduced oxidation formulations
RU2707550C2 (en) 2013-03-13 2019-11-27 Дженентек, Инк. Compositions with reduced oxidation
AR095398A1 (en) 2013-03-13 2015-10-14 Genentech Inc FORMULATIONS WITH REDUCED OXIDATION
CN105392801A (en) 2013-03-15 2016-03-09 比奥根Ma公司 Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
CA2903589A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Cell culture media and methods of antibody production
EP3712252A1 (en) 2013-03-15 2020-09-23 F. Hoffmann-La Roche AG Cell culture compositions with antioxidants and methods for polypeptide production
WO2014210397A1 (en) 2013-06-26 2014-12-31 Academia Sinica Rm2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
WO2015010100A2 (en) 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
DK3036320T3 (en) 2013-08-19 2021-07-12 Biogen Ma Inc MANAGEMENT OF PROTEIN GLYCOSYLATION BY CULTIVATION MEDIA ADDITION AND CELL CULTURE PROCESS PARAMETERS
JP2016538318A (en) 2013-08-28 2016-12-08 ステムセントリックス， インコーポレイテッド New SEZ6 modulator and method of use
PE20160674A1 (en) 2013-08-28 2016-07-21 Stemcentrx Inc METHODS OF CONJUGATION OF SITE-SPECIFIC ANTIBODIES AND COMPOSITIONS
CN105682666B (en) 2013-09-06 2021-06-01 中央研究院 Activation of human iNKT cells using glycolipids
SG11201601770YA (en) 2013-09-12 2016-04-28 Halozyme Inc Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
WO2015048330A2 (en) 2013-09-25 2015-04-02 Biogen Idec Ma Inc. On-column viral inactivation methods
PT3050896T (en) 2013-09-27 2021-08-24 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer
TWI714022B (en) 2013-09-27 2020-12-21 美商建南德克公司 Anti-pdl1 antibody formulations
BR112016011046A2 (en) 2013-11-15 2019-01-29 Centre Nat Rech Scient method for genotyping, method for detecting an infection, kit for detecting an infection and method for detecting in a biological sample.
WO2015095809A1 (en) 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
EP2960252A1 (en) 2014-06-26 2015-12-30 Institut Pasteur Phospholipase for treatment of immunosuppression
CA2935378C (en) 2013-12-24 2023-04-18 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
EP3094352B1 (en) 2014-01-16 2020-09-23 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2016114819A1 (en) 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
JP6736467B2 (en) 2014-02-04 2020-08-05 ジェネンテック， インコーポレイテッド Smoothing mutant and method of using the same
WO2015127407A1 (en) 2014-02-21 2015-08-27 Stemcentrx, Inc. Anti-dll3 antibodies and drug conjugates for use in melanoma
RU2016141307A (en) 2014-03-21 2018-04-24 Регенерон Фармасьютикалз, Инк. EXCELLENT HUMAN ANIMALS THAT MAKE SINGLE-DOMAIN BINDING PROTEINS
DK3122869T3 (en) 2014-03-24 2019-09-09 Biogen Ma Inc PROCEDURES FOR REDUCING GLUTAMINE DEPRESSION IN MAMMAL CULTURE CULTURE
EP3129767B1 (en) 2014-03-27 2021-09-01 Academia Sinica Reactive labelling compounds and uses thereof
WO2015153765A1 (en) 2014-04-01 2015-10-08 Adimab, Llc Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
IL248511B (en) 2014-05-13 2022-07-01 Bavarian Nordic As Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
TWI717319B (en) 2014-05-27 2021-02-01 中央研究院 Fucosidase from bacteroides and methods using the same
TWI679020B (en) 2014-05-27 2019-12-11 中央研究院 Anti-her2 glycoantibodies and uses thereof
KR20170003720A (en) 2014-05-27 2017-01-09 아카데미아 시니카 Anti-cd20 glycoantibodies and uses thereof
KR102494193B1 (en) 2014-05-28 2023-01-31 아카데미아 시니카 Anti-tnf-alpha glycoantibodies and uses thereof
TWI695011B (en) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 Monoclonal antibodies against her2 epitope and methods of use thereof
HUE043847T2 (en) 2014-08-28 2019-09-30 Halozyme Inc Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
CN107001404B (en) 2014-09-08 2021-06-29 中央研究院 Activation of human iNKT cells using glycolipids
EP3193932B1 (en) 2014-09-15 2023-04-26 F. Hoffmann-La Roche AG Antibody formulations
TWI701435B (en) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 Method to determine the reactivity of FVIII
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
TWI700300B (en) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 Antibodies that neutralize substances with the function of FVIII coagulation factor (FVIII)
MA41685A (en) 2014-10-17 2017-08-22 Biogen Ma Inc COPPER SUPPLEMENT FOR THE REGULATION OF GLYCOSYLATION IN A MAMMAL CELL CULTURE PROCESS
MA40864A (en) 2014-10-31 2017-09-05 Biogen Ma Inc HYPOTAURINE, GABA, BETA-ALANINE AND CHOLINE FOR THE REGULATION OF THE ACCUMULATION OF RESIDUAL BY-PRODUCTS IN MAMMAL CELL CULTURE PROCESSES
US10208120B2 (en) 2014-11-05 2019-02-19 Genentech, Inc. Anti-FGFR2/3 antibodies and methods using same
US11033637B2 (en) 2014-11-21 2021-06-15 University Of Maryland, Baltimore Targeted structure-specific particulate delivery systems
US11543411B2 (en) 2014-12-05 2023-01-03 Prelude Corporation DCIS recurrence and invasive breast cancer
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
CN107430127B (en) 2015-01-24 2020-08-28 中央研究院 Cancer markers and methods of use thereof
JP6779887B2 (en) 2015-01-24 2020-11-04 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ New glycan conjugate and how to use it
KR102620346B1 (en) 2015-01-30 2024-01-02 아카데미아 시니카 Compositions and Methods Related to Universal Glycoforms for Enhanced Antibody Efficacy
EP4177267A1 (en) 2015-02-02 2023-05-10 Children's Health Care d/b/a Children's Minnesota Anti-surrogate light chain antibodies
CA2975875A1 (en) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened and methods of using the same
WO2016149678A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
EP3279216A4 (en) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
US10787500B2 (en) 2015-04-10 2020-09-29 Adimab, Llc Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
EP3285811A1 (en) 2015-04-21 2018-02-28 Institut Gustave Roussy Therapeutic methods, products and compositions inhibiting znf555
CN107922497B (en) 2015-06-24 2022-04-12 詹森药业有限公司 anti-VISTA antibodies and fragments
TWI797060B (en) 2015-08-04 2023-04-01 美商再生元醫藥公司 Taurine supplemented cell culture medium and methods of use
EP3344806A4 (en) 2015-09-04 2019-03-20 OBI Pharma, Inc. Glycan arrays and method of use
EP3398965A4 (en) 2015-12-28 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of fc region-containing polypeptide
WO2017117311A1 (en) 2015-12-30 2017-07-06 Genentech, Inc. Formulations with reduced degradation of polysorbate
US20170239355A1 (en) 2015-12-30 2017-08-24 Genentech, Inc. Use of tryptophan derivatives for protein formulations
WO2017136558A1 (en) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened and methods of using the same
TWI756204B (en) 2016-02-12 2022-03-01 比利時商楊森製藥公司 Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
CA3016170A1 (en) 2016-03-08 2017-09-14 Academia Sinica Methods for modular synthesis of n-glycans and arrays thereof
EP3429693B1 (en) 2016-03-15 2023-08-23 Mersana Therapeutics, Inc. Napi2b-targeted antibody-drug conjugates and methods of use thereof
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
CA3018365A1 (en) 2016-03-23 2017-09-28 The General Hospital Corporation Assays and methods for detecting udp-glucose
CA3019560A1 (en) 2016-03-29 2017-10-05 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
WO2017172771A2 (en) 2016-03-29 2017-10-05 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
EP3440208B1 (en) * 2016-04-06 2020-09-16 Zumutor Biologics, Inc. Vectors for cloning and expression of proteins, methods and applications thereof
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
KR20230110820A (en) 2016-04-22 2023-07-25 오비아이 파머 인코퍼레이티드 Cancer immunotherapy by immune activation or immune modulation via globo series antigens
WO2018022479A1 (en) 2016-07-25 2018-02-01 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
EP3490592A4 (en) 2016-07-27 2020-03-25 OBI Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
WO2018023121A1 (en) 2016-07-29 2018-02-01 Obi Pharma, Inc. Human antibodies, pharmaceutical compositions and methods
JP7213549B2 (en) 2016-08-22 2023-01-27 シーエイチオー ファーマ インコーポレイテッド Antibodies, Binding Fragments, and Methods of Use
JP7125932B2 (en) 2016-09-06 2022-08-25 中外製薬株式会社 Methods of Using Bispecific Antibodies Recognizing Coagulation Factor IX and/or Activated Coagulation Factor IX and Coagulation Factor X and/or Activated Coagulation Factor X
CA3037961A1 (en) 2016-09-30 2018-04-05 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody
KR20190078648A (en) 2016-11-16 2019-07-04 얀센 바이오테크 인코포레이티드 Methods for treating psoriasis with anti-IL23 specific antibodies
EP3541414A4 (en) 2016-11-21 2020-11-11 OBI Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
EP3573658A4 (en) 2017-01-30 2021-07-21 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
JP2020506947A (en) 2017-02-07 2020-03-05 ヤンセン バイオテツク，インコーポレーテツド Anti-TNF antibodies, compositions and methods for treating active ankylosing spondylitis
TW201922780A (en) 2017-09-25 2019-06-16 美商健生生物科技公司 Safe and effective method of treating Lupus with anti-IL12/IL23 antibody
BR112020005834A2 (en) 2017-09-29 2020-09-24 Chugai Seiyaku Kabushiki Kaisha multispecific antigen binding molecule having blood clotting factor viii cofactor function (fviii) replacement activity, and pharmaceutical formulation containing said molecule as an active ingredient
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
EP3530282A1 (en) 2018-02-27 2019-08-28 Diaccurate Therapeutic methods
KR20200129125A (en) 2018-03-05 2020-11-17 얀센 바이오테크 인코포레이티드 How to treat Crohn's disease with anti-IL23 specific antibodies
KR20200131838A (en) * 2018-03-14 2020-11-24 에프. 호프만-라 로슈 아게 Methods for affinity maturation of antibodies
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
EP3833389A1 (en) 2018-08-08 2021-06-16 Genentech, Inc. Use of tryptophan derivatives and l-methionine for protein formulation
WO2020056338A1 (en) 2018-09-14 2020-03-19 Prelude Corporation Method of selection for treatment of subjects at risk of invasive breast cancer
SI3883606T1 (en) 2018-09-24 2023-10-30 Janssen Biotech, Inc. Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
CA3113818A1 (en) 2018-10-05 2020-04-09 Bavarian Nordic A/S Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
US11548941B2 (en) 2018-11-20 2023-01-10 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
SG11202104918PA (en) 2018-11-20 2021-06-29 Bavarian Nordic As Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l
EP3897722A4 (en) 2018-12-18 2022-09-14 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody
EP3911676A1 (en) 2019-01-15 2021-11-24 Janssen Biotech, Inc. Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis
KR20210118878A (en) 2019-01-23 2021-10-01 얀센 바이오테크 인코포레이티드 Anti-TNF antibody composition for use in a method of treating psoriatic arthritis
EP3693063A1 (en) 2019-02-06 2020-08-12 Diaccurate Methods and compositions for treating cancer
KR20210141998A (en) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 Method of making anti-TNF antibody composition
JP2022525145A (en) 2019-03-14 2022-05-11 ヤンセン バイオテツク，インコーポレーテツド A production method for producing an anti-IL12 / IL23 antibody composition.
MA55283A (en) 2019-03-14 2022-01-19 Janssen Biotech Inc METHODS FOR PRODUCING ANTI-TNF ANTIBODY COMPOSITIONS
MA55282A (en) 2019-03-14 2022-01-19 Janssen Biotech Inc MANUFACTURING METHODS FOR THE PRODUCTION OF ANTI-TNF ANTIBODY COMPOSITIONS
EA202192459A1 (en) 2019-03-18 2021-11-25 Янссен Байотек, Инк. METHOD FOR TREATMENT OF PSORIASIS WITH ANTIBODY TO IL12 / IL23 IN CHILDREN
SG11202111345PA (en) 2019-04-19 2021-11-29 Chugai Pharmaceutical Co Ltd Chimeric receptor that recognizes engineered site in antibody
KR20220012883A (en) 2019-05-23 2022-02-04 얀센 바이오테크 인코포레이티드 A method of treating inflammatory bowel disease with a combination therapy of IL-23 and an antibody against TNF alpha
CA3142580A1 (en) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
EP3976648A1 (en) 2019-06-03 2022-04-06 Janssen Biotech, Inc. Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
JPWO2021010326A1 (en) 2019-07-12 2021-01-21
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
EP4061406A1 (en) 2019-11-20 2022-09-28 Bavarian Nordic A/S Recombinant mva viruses for intratumoral and/or intravenous administration for treating cancer
WO2021239666A1 (en) 2020-05-26 2021-12-02 Diaccurate Therapeutic methods
CA3212729A1 (en) 2021-03-12 2022-09-15 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
AU2022232007A1 (en) 2021-03-12 2023-10-26 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
WO2023281462A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
KR20240032991A (en) 2021-07-09 2024-03-12 얀센 바이오테크 인코포레이티드 Manufacturing Methods for Producing Anti-TNF Antibody Compositions
US20230038355A1 (en) 2021-07-09 2023-02-09 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions
WO2023073615A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
US20230151087A1 (en) 2021-11-15 2023-05-18 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
US20230159633A1 (en) 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
WO2023187707A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of treating mild to moderate psoriasis with il-23 specific antibody
WO2023223265A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU6235294A (en) * 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing polypeptide binding sites
AU6132994A (en) * 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing antibody libraries using universal or randomized immunoglobulin light chains

Also Published As

Publication number Publication date
DE69530305D1 (en) 2003-05-15
EP0779933B1 (en) 2003-04-09
US5667988A (en) 1997-09-16
EP0779933A4 (en) 1999-10-06
ES2196077T3 (en) 2003-12-16
DK0779933T3 (en) 2003-07-28
DE69530305T2 (en) 2004-02-12
JPH10504970A (en) 1998-05-19
ATE236992T1 (en) 2003-04-15
AU3504695A (en) 1996-03-27
PT779933E (en) 2003-08-29
AU706343B2 (en) 1999-06-17
EP0779933A1 (en) 1997-06-25
WO1996007754A1 (en) 1996-03-14
CA2198899C (en) 2010-02-23
US6096551A (en) 2000-08-01

Similar Documents

Publication Publication Date Title
CA2198899A1 (en) Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
CA2460639C (en) Engineered templates and their use in single primer amplification
Embleton et al. In-cell PCR from mRNA: amplifying and linking the rearranged immunoglobulin heavy and light chain V-genes within single cells
US6265150B1 (en) Phage antibodies
CA2278585C (en) A method for in vitro molecular evolution of protein function
Jirholt et al. Exploiting sequence space: shuffling in vivo formed complementarity determining regions into a master framework
AU724651B2 (en) Phage-display of immunoglobulin heavy chain libraries for identification of inhibitors of intracellular constituents
AU2007211861B2 (en) Methods of Constructing Display Libraries of Genetic Packages for Members of a Diverse Family of Peptides
AU2002341752A1 (en) Engineered templates and their use in single primer amplification
JP2005514927A5 (en)
Okamoto et al. Optimal construction of non-immune scFv phage display libraries from mouse bone marrow and spleen established to select specific scFvs efficiently binding to antigen
Söderlind et al. Domain libraries: synthetic diversity for de novo design of antibody V-regions
AU2004305055B2 (en) Engineered templates and their use in single primer amplification
JP2003529368A (en) Methods for in vitro molecular evolution of antibody function
WO2003104434A2 (en) A method to amplify variable sequences without imposing primer sequences
JP6974909B2 (en) HC-CDR3-only library with reduced combinatorial redundancy and optimized loop length distribution
JPH08116978A (en) Preparation of antibody fab library
San Kim et al. Improvement of anti-Burkholderia mouse monoclonal antibody from various phage-displayed single-chain antibody libraries
ATALAY et al. The Use of Polypeptide Probes Selected FromArtificial Peptide Libraries for the Recognitionand Differentiation of DNA Sequences
Alkon et al. New Method for Rapid Screening of VHH clones Selected by Ribosome Display
EP1789548B1 (en) Antibody libraries
Koohapitagtam et al. Efficient amplification of light and heavy chain variable regions and construction of a non-immune phage scFv library
AU715757B2 (en) Phage-display of immunoglobulin heavy chain libraries
Baek et al. Isolation of two distinct populations of recombinant antibody molecules specific for rat malonyl-CoA decarboxylase from a semi-synthetic human scFv display library using Ex-phage system
KR20180092072A (en) Antibody Libraries Having high performance, high productivity and Methods for Preparation of Them

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20150901